Can a Follow-Up drug deepen remission in myeloma patients?
NCT ID NCT06523621
First seen Jan 22, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This phase 2 study tests whether adding nivolumab after CAR-T cell therapy (ide-cel) can improve outcomes for people with relapsed/refractory multiple myeloma who did not achieve a complete response. The trial enrolled 1 adult participant with measurable disease and good performance status. The main goal is to see if the combination leads to a complete or stringent complete response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.